Gut bacteria boost? new combo therapy aims to improve lung cancer outcomes
NCT ID NCT06943235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding probiotics (good bacteria) to standard chemoradiation and immunotherapy can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 60 adults aged 18-80 will take part. The goal is to see if this combination is safe and improves treatment response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED STAGE SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut check: could sauerkraut and fiber help fight cancer?
- New drug combo aims to fight lung cancer after chemoradiation
- New drug combo aims to keep lung cancer at bay longer
- New drug aims to shield cancer patients from chemo side effects
- New drug cocktail aims to control aggressive lung cancer
- New immunotherapy combo shows promise for tough lung cancer